Dongsung Pharmaceutical Corporate Governance Report: Post-rehabilitation, no dividends and many CG non-compliances raise concerns for shareholder value
Rehabilitation completion and new board: Dongsung Pharmaceutical underwent rehabilitation from June 2025 to May 2026, and subsequently formed a new board with 1 inside director, 4 independent directors, and 2 non-executive directors.
No dividends or shareholder returns: The company has paid no cash dividends for the last three fiscal years (2023-2025), and lacks a formal dividend policy or shareholder return plan, offering zero predictability.
Multiple non-compliance with CG key indicators: Out of 15 key corporate governance indicators, the company failed to comply with 11, including 4-week notice for AGM, dividend predictability, CEO succession policy, enterprise risk management, board gender diversity, and independence of internal audit support.
Designation as unfaithful disclosure entity: In July and October 2025, the company was designated as an unfaithful disclosure entity due to false corrective disclosure and delayed disclosure of management dispute lawsuits, incurring 8.5 penalty points and a fine of KRW 85 million.
Convertible bond issuance with limited dilution: Issued KRW 5 billion in private CB (series 37) in April 2026 with a conversion price of KRW 1,000 (near current price of KRW 973), limiting dilution risk but with unclear use of proceeds.
Management dispute and low shareholder approval: At the September 2025 EGM, director election proposals received only 51.9% approval, reflecting deep shareholder divisions due to management conflict.
[AI Summary]Dongsung Pharmaceutical has successfully exited rehabilitation and established a new governance framework, but the absence of dividends, multiple CG non-compliances, and past disclosure violations will likely prolong shareholder confidence recovery. The lack of a shareholder return policy and weak internal controls pose ongoing investment risks; near-term stock catalysts depend less on operational performance and more on the speed of governance improvements.